Stock information

 

Be invited to scroll down for detailed information regarding the Evotec SE share, ranging from basic share data to our dividend policy.  

Basic share data

Security identification numbers:
Frankfurt Stock Exchange
(ordinary bearer shares)
ISIN: DE0005664809
OTC Markets, OTCBB
(American Depositary Shares, ADSs)
CUSIP: 30050E105
ISIN: US30050E1055

Ticker symbol:
Frankfurt Stock Exchange: EVT
OTC Markets, OTCBB: EVTCY

Bloomberg Xetra: EVT GY Equity

Bloomberg OTC Markets, OTCBB: EVTCY US Equity
Reuters Xetra: EVTG.DE

Stock exchange:
Frankfurt Stock Exchange
OTC Markets, OTCBB

Segment:
Prime Standard

Index:
MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX

Designated sponsor:
ODDO SEYDLER BANK AG

Paying agent:
Deutsche Bank AG, Frankfurt am Main

Number of shares issued:
150,582,360 ordinary bearer shares

Nominal capital:
€ 150,740,530

Security identification numbers:
Frankfurt Stock Exchange
(ordinary bearer shares)
ISIN: DE0005664809
OTC Markets, OTCBB
(American Depositary Shares, ADSs)
CUSIP: 30050E105
ISIN: US30050E1055
 

Ticker symbol:
Frankfurt Stock Exchange: EVT
OTC Markets, OTCBB: EVTCY

Bloomberg Xetra: EVT GY Equity

Bloomberg OTC Markets, OTCBB: EVTCY US Equity
Reuters Xetra: EVTG.DE

 

Stock exchange:
Frankfurt Stock Exchange
OTC Markets, OTCBB

 

Segment:
Prime Standard

 

Index:
MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX

 

Designated sponsor:
ODDO SEYDLER BANK AG

 

Paying agent:
Deutsche Bank AG, Frankfurt am Main

 

Number of shares issued:
150,582,360 ordinary bearer shares

 

Nominal capital:
€ 150,740,530

 

Share Price Summary 2018 (XETRA)

High (04 Sept):
€ 23.36
Low (10 May):
€ 12.07
Opening Price:
€ 13.55
Closing Price:
€ 17.37
Weighted average number of shares outstanding:
147,482,051
Total number of shares outstanding as at 31 Dec:
149,062,794
Average daily trading volume (all exchanges):
1,440,924 shares
Market capitalisation as at 31 Dec:
€ 2,586.8 m
Earnings per share (diluted/basic):
€ 0.56/€ 0.57
Dividend per share:
€ 0.00
High (04 Sept):
€ 23.36
 
Low (10 May):
€ 12.07
 
Opening Price:
€ 13.55
 
Closing Price:
€ 17.37
 
Weighted average number of shares outstanding:
147,482,051
 
Total number of shares outstanding as at 31 Dec:
149,062,794
 
Average daily trading volume (all exchanges):
1,440,924 shares
 
Market capitalisation as at 31 Dec:
€ 2,586.8 m
 
Earnings per share (diluted/basic):
€ 0.56/€ 0.57
 
Dividend per share:
€ 0.00
 

Stock Price & Chart

 

Shareholder structure

At the end of November 2019, the number of total voting rights amounts to 150,740,530.

Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de.

Three major shareholders, Novo Holdings A/S, ROI Verwaltungsgesellschaft mbH/Roland Oetker, The Goldman Sachs Group, Inc., and Morgan Stanley have exceeded the threshold of 5%. The free float according to the definition of the Frankfurt Stock Exchange is approx. 57% according to our estimates (Evotec: 11|2019).

Shareholder structure (in %)*

*All stated shareholdings comprise the total of voting rights attached to shares and instruments

 

Financial analysts

Overview of analysts covering the Evotec share

Bankhaus Lampe Volker Braun Bankhaus Lampe KG Jägerhofstraße 10 40479 Düsseldorf Germany

Berenberg Capital Markets LLC Patrick Trucchio Berenberg Capital Markets LLC 1251 Avenue of the Americas, 53rd Floor New York, NY 10020 USA

Deutsche Bank Falko Friedrichs Gunnar Romer gunnar.romer@db.com Deutsche Bank AG Große Gallusstraße 10-14 60311 Frankfurt am Main Germany

EQUI.TS GmbH Thomas Schießle EQUI.TS GmbH Am Schieferstein 1 60435 Franfkurt am Main Germany

goetzpartners securities Limited Brigitte de Lima goetzpartners securities Limited The Stanley Building 7 Pancras Square London N1C 4AG United Kingdom

Intron Health Naresh Chouhan New Street Research LLP 11 Austin Friars London, EC2N 2HG

Kempen & Co. N.V. Alexandru Cogut alexandru.cogut@kempen.com Kempen & Co. N.V. Beethovenstraat 300 P.O. Box 75666 1070 AR Amsterdam The Netherlands

Ladenburg Thalmann & Co. Inc. Michael Higgins Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Flr New York, NY 10172 USA

Rx Securities Dr Samir Devani Rx Securities Third Floor 1 Fore Street, Moorgate London EC2Y 9DT United Kingdom

 

Important note:

Evotec is monitored and assessed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Evotec’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Evotec or its management. Evotec does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Evotec has no obligation to update or supplement the above information and makes no representation or warranty as to the accuracy and completeness of this list.

Copies of the research reports of the above-named analysts must be obtained directly from the analysts or their employers. Evotec is not able to publish the research reports due to legal considerations.

Initial public offering information*

 

  • Segment: Neuer Markt, Frankfurt Stock Exchange
  • Offering structure: Public Offering in Germany, Private placement outside Germany, Rule 144A offering in the USA
  • Offer shares: 4,927,500 Offer shares each with an imputed share in the capital stock of € 1.00 per share, of which:
    4,100,000 New shares issued from a capital increase
    182,500 Shares sold by the selling shareholder
    645,00 Over-Allotment option from a capital increase
  • Global coordinators: UBS Warburg AG, Deutsche Bank AG
  • Further managers: SG Investment Banking, Sal. Oppenheim, Hamburger Sparkasse
  • Bookbuilding period: 02 November 1999 - 08 November 1999
  • Offering price: € 13.00
  • Listing: 10 November 1999
  • Opening price: € 24.00
  • Subscribed capital: € 12,078,000

*All data not adjusted for stock split of 18 August 2000

Dividend

Evotec currently intends to retain any potential future profits and reinvest them in the Company’s further growth strategy. Payment of dividends is in addition dependent upon Evotec SE’s financial situation and liquidity requirements, the general market conditions and statutory, tax and regulatory requirements. Evotec SE is only allowed to pay dividends if the generated net income exceeds the loss carry forwards. Currently, no distributable profits exist in Evotec SE. 

 

Contact us

Gabriele Hansen

SVP, Corporate Communications, Marketing & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Anja Ben Lekhal

Investor Relations Associate

T + 49 40 56081 210 F +49 40 56081 222 vCard
TOP